Aurovela 1.5/30 Tablet
Product Images NDC 65862-935

8 FDA label images from Aurobindo Pharma Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Aurovela 1.5/30 (NDC 65862-935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Norethindroneethinyl Fig1)

Chemical Structure (Norethindroneethinyl Fig1)
A bar chart depicting circulatory disease mortality rates per 100,000 woman-years by age group (15-24, 25-34, 35-44, 45-) comparing smoking status and oral contraceptive use. It differentiates mortality among ever-users and controls, with separate bars for smokers and non-smokers across each age group.*
FDA Label Image

Figure 2 (Norethindroneethinyl Fig2)

Figure 2 (Norethindroneethinyl Fig2)
A forest plot comparing the effect estimates of ever or current use of combined oral contraceptives (COC) versus never use from multiple cohort studies. The plot displays study names, effect estimates with confidence intervals, and measures such as odds ratio (OR), relative risk (RR), and hazard ratio (HR) along an effect estimate axis ranging approximately from -1.50 to 2.00.*
FDA Label Image

Figure 3 (Norethindroneethinyl Fig3)

Figure 3 (Norethindroneethinyl Fig3)
An instructional diagram for Aurovela 1.5/30 (norethindrone acetate and ethinyl estradiol) tablets. It shows a weekly pill calendar with rows labeled Week 1, Week 2, and Week 3, and columns for each day of the week from Sunday to Saturday. The diagram instructs on starting the medication on Sunday or on the first day of menstruation for Day-1 starters, and indicates the direction of pill-taking from left to right each week.*
FDA Label Image

Package Label-principal Display Panel (1.5 mg/30 mcg Pouch Label)

Package Label-principal Display Panel (1.5 mg/30 mcg Pouch Label)
An instructional diagram for Aurovela 1.5/30 tablets showing a weekly pill pack with labeled days Sunday through Saturday. It directs users to start on Sunday or the first day of their period (Day-1 starters) and indicates the direction to take pills from left to right each week. Arrows mark the starting points and progression through three weeks of tablets.*
FDA Label Image

Package Label-principal Display Panel (1.5 mg/30 mcg Blister Carton)

Package Label-principal Display Panel (1.5 mg/30 mcg Blister Carton)
Label of Aurovela 1.5/30 oral tablets by Aurobindo Pharma Limited. The product contains norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg per tablet, provided in a 21-tablet pouch for a 21-day regimen. The label includes usage warnings and manufacturing details.*
FDA Label Image

Norethindroneethinyl Fig6

Norethindroneethinyl Fig6
Aurovela 1.5/30 (norethindrone acetate and ethinyl estradiol tablets USP) oral tablet packaging label showing a carton that contains three pouches, each with 21 tablets. The label displays product warnings, dosage instructions, and storage conditions, with the manufacturer listed as Aurobindo Pharma Limited and distribution by Aurobindo Pharma USA, Inc. The label includes barcodes and a color gradient from beige to purple.*
FDA Label Image

Norethindrone Chemical Structure (Norethindroneethinyl Str1)

Norethindrone Chemical Structure (Norethindroneethinyl Str1)
Chemical structure of Norethindrone Acetate, the active ingredient in Aurovela 1.5/30. The diagram shows the molecular arrangement including rings and functional groups characteristic of this steroidal compound.*
FDA Label Image

Ethinylestradiol Chemical Structure (Norethindroneethinyl Str2)

Ethinylestradiol Chemical Structure (Norethindroneethinyl Str2)
Chemical structure of Ethinyl Estradiol, showing a multi-ring steroid framework with hydroxyl groups and an ethynyl side chain, labeled clearly beneath the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.